A randomized, phase II trial of oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence. - Heumann, Thatcher R.; Baretti, Marina; Sugar, Elizabeth A.; Durham, Jennifer N.; Linden, Sheila; Lopez-Vidal, Tamara Y.; Leatherman, James; Cope, Leslie; Sharma, Anup; Weekes, Colin D.; O'Dwyer, Peter J.; Reiss, Kim A.; et al. (Clinical Epigenetics, 2022)